Hiroki Matsumoto

Professor

The Univeristy of Tokyo

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Immunology Immunology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Hiroki Matsumoto is a Professor at The University of Tokyo in Japan. His research primarily focuses on the application of copper-64 in cancer diagnosis and treatment, as evidenced by his recent articles addressing topics such as the characterization of Cu-labeled antibodies and the effects of trace metal impurities in therapeutic formulations. Additionally, he investigates innovative methods for monitoring tumor characteristics and responses to targeted therapies.

Articles (10)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (4)

Masashi Takahashi

Professor

Toho University

JAPAN

View details

Kohshin Washiyama

Associate Professor

Fukushima Medical University

JAPAN

View details

Mitsumasa Taguchi

National Institutes for Quantum and Radiological Science and Technology

JAPAN

View details

Mitsuhiro Shinada

National Institutes for Quantum and Radiological Science and Technology

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hiroki Matsumoto

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

64Cu2+ Complexes of Tripodal Amine Ligands’ In Vivo Tumor and Liver Uptakes and Intracellular Cu Distribution in the Extrahepatic Bile Duct Carcinoma Cell Line TFK-1: A Basic Comparative Study

Trace Metal Impurities Effects on the Formation of [64Cu]Cu-diacetyl-bis(N4-methylthiosemicarbazone) ([64Cu]Cu-ATSM)

An In Vivo Dual-Observation Method to Monitor Tumor Mass and Tumor-Surface Blood Vessels for Developing Anti-Angiogenesis Agents against Submillimeter Tumors

Process to Remove the Size Variants Contained in the Antibody–Chelator Complex PCTA-NCAB001 for Radiolabeling with Copper-64

Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET

In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized <sup>64</sup>Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study

Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomography

Efficacy of vorinostat-sensitized intraperitoneal radioimmunotherapy with 64 Cu-labeled cetuximab against peritoneal dissemination of gastric cancer in a mouse model

Identification and quantitative structure–activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [<sup>64</sup>Cu]Cu-ATSM

Evaluation of aminopolycarboxylate chelators for whole-body clearance of free<sup>225</sup>ac: A feasibility study to reduce unexpected radiation exposure during targeted alpha therapy

Collaborators (4)

Masashi Takahashi

Kohshin Washiyama

Mitsumasa Taguchi

Mitsuhiro Shinada

Make your next move.